Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma : a multi-center observational study
OBJECTIVE: To describe the impact of nebulized budesonide inhalation suspension (BIS) on guardian-reported symptoms in Chinese pediatric patients with cough variant asthma (CVA).
METHODS: This was a secondary analysis of a prospective, non-interventional study conducted at 39 Chinese sites. Patients with CVA aged ≤5 years were classified according to the severity of baseline symptoms: mild (symptom score ≤3) or severe (symptom score >3). Daytime and night-time symptom scores, disease control, use of bronchodilators, and improvements in symptoms control were compared after 1, 3, 5 and 7 weeks of treatment between groups.
RESULTS: Among 914 patients, 821 (89.8%) completed the 7-week treatment. Among all patients, 368 (40.3%) were classified as mild CVA and 529 (57.9%), as severe CVA. Symptom scores in the severe group were higher than those in the mild group at weeks 1, 3, and 5 (p < 0.05), but not at week 7 (p > 0.05). Further, more patients in the mild group achieved disease control at any time point (98.6% at 3 weeks and 99.7% at 7 weeks), compared with the patients in the severe group (p < 0.001). The proportion of patients requiring bronchodilators differed between the groups until week 5 (p < 0.001). No severe or drug-related adverse events were reported.
CONCLUSIONS: Individualized BIS treatment should be formulated according to the severity of baseline symptoms in CVA patients. Patients with mild CVA showed improvement after a shorter treatment time, while patients with severe CVA might require a longer time to respond to the treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
The Journal of asthma : official journal of the Association for the Care of Asthma - 53(2016), 5 vom: 18. Juni, Seite 532-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Xiaojian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.02.2017 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3109/02770903.2015.1111903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM254170463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM254170463 | ||
| 003 | DE-627 | ||
| 005 | 20231224171810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/02770903.2015.1111903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0847.xml |
| 035 | |a (DE-627)NLM254170463 | ||
| 035 | |a (NLM)26517446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Xiaojian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma |b a multi-center observational study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2017 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To describe the impact of nebulized budesonide inhalation suspension (BIS) on guardian-reported symptoms in Chinese pediatric patients with cough variant asthma (CVA) | ||
| 520 | |a METHODS: This was a secondary analysis of a prospective, non-interventional study conducted at 39 Chinese sites. Patients with CVA aged ≤5 years were classified according to the severity of baseline symptoms: mild (symptom score ≤3) or severe (symptom score >3). Daytime and night-time symptom scores, disease control, use of bronchodilators, and improvements in symptoms control were compared after 1, 3, 5 and 7 weeks of treatment between groups | ||
| 520 | |a RESULTS: Among 914 patients, 821 (89.8%) completed the 7-week treatment. Among all patients, 368 (40.3%) were classified as mild CVA and 529 (57.9%), as severe CVA. Symptom scores in the severe group were higher than those in the mild group at weeks 1, 3, and 5 (p < 0.05), but not at week 7 (p > 0.05). Further, more patients in the mild group achieved disease control at any time point (98.6% at 3 weeks and 99.7% at 7 weeks), compared with the patients in the severe group (p < 0.001). The proportion of patients requiring bronchodilators differed between the groups until week 5 (p < 0.001). No severe or drug-related adverse events were reported | ||
| 520 | |a CONCLUSIONS: Individualized BIS treatment should be formulated according to the severity of baseline symptoms in CVA patients. Patients with mild CVA showed improvement after a shorter treatment time, while patients with severe CVA might require a longer time to respond to the treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Baseline symptoms | |
| 650 | 4 | |a budesonide suspension nebulization treatment | |
| 650 | 4 | |a cough variant asthma | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Suspensions |2 NLM | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 700 | 1 | |a Hong, Jianguo |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Huanji |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Juanjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a He, Shaoru |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xiaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Changchong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of asthma : official journal of the Association for the Care of Asthma |d 1988 |g 53(2016), 5 vom: 18. Juni, Seite 532-7 |w (DE-627)NLM01328827X |x 1532-4303 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2016 |g number:5 |g day:18 |g month:06 |g pages:532-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/02770903.2015.1111903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2016 |e 5 |b 18 |c 06 |h 532-7 | ||